Unrelated Donor Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma: Long-Term Outcomes

Koen van Besien, Jeanette Carreras, Philip J. Bierman, Brent R. Logan, Arturo Molina, Roberta King, Gene Nelson, Joseph W. Fay, Richard E. Champlin, Hillard M. Lazarus, Julie M. Vose, Parameswaran N. Hari

Research output: Contribution to journalArticlepeer-review

28 Scopus citations


We analyzed the outcomes of 283 patients receiving unrelated donor allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma (NHL) facilitated by the Center for International Blood and Marrow Transplant Research/National Marrow Donor Program (CIBMTR/NMDP) between 1991 and 2004. All patients received myeloablative conditioning regimens. The median follow-up of survivors is 5 years. Seventy-three (26%) patients are alive. The day 100 probability of death from all causes is estimated at 39%. The cumulative incidence of developing grade III-IV acute graft-versus-host disease (aGVHD) at day 100 is 25%. The estimated 5-year survival and failure free survival are 24% (95% confidence interval [CI]: 19-30) and 22% (95% CI: 17-28), respectively. Factors adversely associated with overall survival (OS) included increasing age, decreased performance status, and refractory disease. Follicular lymphoma (FL) and peripheral T cell lymphoma had improved survival compared to aggressive B cell lymphomas. Factors adversely associated with progression-free survival (PFS) included performance status, histology, and disease status at transplant. Long-term failure-free survival is possible following unrelated donor transplantation for NHL, although early mortality was high in this large cohort.

Original languageEnglish (US)
Pages (from-to)554-563
Number of pages10
JournalBiology of Blood and Marrow Transplantation
Issue number5
StatePublished - May 2009


  • Lymphoma
  • Myeloablative
  • Unrelated donor

ASJC Scopus subject areas

  • Hematology
  • Transplantation


Dive into the research topics of 'Unrelated Donor Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma: Long-Term Outcomes'. Together they form a unique fingerprint.

Cite this